Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $45.85 USD
Change Today -0.08 / -0.17%
Volume 339.3K
PTLA On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

portola pharmaceuticals inc (PTLA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/22/15 - $49.37
52 Week Low
07/28/14 - $23.34
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

portola pharmaceuticals inc (PTLA) Related Businessweek News

No Related Businessweek News Found

portola pharmaceuticals inc (PTLA) Details

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III clinical trial for venous thromboembolism prophylaxis in acute medically ill patients in-hospital and post discharge. The company’s other lead development candidate, Andexanet alfa, a recombinant protein that is in Phase III registration studies designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. It has collaboration agreements with Biogen Idec Inc.; Bristol-Myers Squibb Company; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Lee’s Pharmaceutical (HK) Ltd. The company is also developing Cerdulatinib, which is in Phase I/IIa proof-of-concept study, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases enzymes, which regulate signaling pathways, as well as for hematologic, or blood, cancers, and inflammatory disorders. In addition, it is involved in the development of PRT2607, a selective Syk inhibitor. The company was founded in 2003 and is headquartered in South San Francisco, California.

99 Employees
Last Reported Date: 03/2/15
Founded in 2003

portola pharmaceuticals inc (PTLA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $450.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $398.1K
Executive Vice President of Research and Deve...
Total Annual Compensation: $401.9K
Compensation as of Fiscal Year 2014.

portola pharmaceuticals inc (PTLA) Key Developments

Portola Pharmaceuticals Announces in Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban

Portola Pharmaceuticals announced results of a study demonstrating that andexanet alfa significantly reduced bleeding in a validated animal model of bleeding using the Factor Xa inhibitor rivaroxaban as the anticoagulant. The reduction in blood loss correlated with reversal of the anticoagulant effects of rivaroxaban as measured by anti-Factor Xa activity, a definitive pharmacodynamic measurement of the anticoagulant activity of Factor Xa inhibitors. In contrast, the four-factor prothrombin complex concentrate (PCC) Kcentra did not impact bleeding or the anti-Factor Xa coagulation biomarker in the study. The results were presented in an oral session at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress in Toronto. Andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, is a recombinant protein specifically designed to reverse the anticoagulant activity in patients treated with an oral or injectable Factor Xa inhibitor. Andexanet alfa has the potential to be a first-in-class antidote for anticoagulated patients who suffer a major bleeding episode or require emergency surgery. Portola is currently evaluating the antidote in two randomized, placebo-controlled Phase 3 ANNEXA™ registration studies with apixaban and rivaroxaban and in a Phase 4 confirmatory study in patients receiving apixaban, rivaroxaban or enoxaparin who present with an acute major bleed.

Portola Pharmaceuticals, Bristol-Myers Squibb Company and Pfizer Inc. Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study

Portola Pharmaceuticals, Bristol-Myers Squibb Company and Pfizer Inc. announced full results from the second part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study. This registration-enabling study evaluated the safety and efficacy of andexanet alfa, an investigational antidote and U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, administered as an intravenous (IV) bolus followed by a continuous two-hour infusion to sustain the reversal of anticoagulation activity of the Factor Xa inhibitor Eliquis (apixaban) in healthy volunteers ages 50-75 years. This second part of the study achieved all primary and pre-specified secondary endpoints with high statistical significance. Andexanet alfa produced rapid reversal of the anticoagulant effect of Eliquis, as measured by anti-Factor Xa activity, which was sustained for the duration of the infusion. Andexanet alfa significantly reduced the level of free unbound Eliquis in the plasma and restored thrombin generation to normal. Andexanet alfa was well tolerated, with no serious adverse events, thrombotic events, or antibodies to Factor X or Xa reported. Mild infusion reactions were reported in six subjects: four in the andexanet arm and two in the placebo arm. No subjects discontinued the study due to an adverse event. The full data set was presented in a Late-Breaking Clinical Trial oral session at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress in Toronto. Portola plans to submit data from the ANNEXA-A (apixaban) and ANNEXA-R (rivaroxaban) studies, and initial data from a Phase 4 study, as part of its Biologics License Application (BLA) to the FDA under an Accelerated Approval pathway by the end of 2015.

Portola Pharmaceuticals, Inc. Appoints Tao Fu as Executive Vice President, Chief Commercial and Business Officer

Portola Pharmaceuticals, Inc. announced the appointment of Tao Fu as executive vice president, chief commercial and business officer, effective immediately. Mr. Fu joins Portola from Bristol-Myers Squibb (BMS), where he was vice president and head of mergers and acquisitions and alliance management. At Portola, Mr. Fu will be responsible for the company's commercial operations and business development and will serve on the Executive Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTLA:US $45.85 USD -0.08

PTLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTLA.
View Industry Companies

Industry Analysis


Industry Average

Valuation PTLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 234.7x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 205.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PORTOLA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at